Can they list on higher exchange abd do lawsuit at same time?

Seems like RS and higher exchange is the most likely plan now

Learned a good deal about trading/investing/stock market/building companies here. It has been a blast! (As long as there is some sort of payout and not just an expensive course)

This has been one wild and crazy ride so far

#GOH

2025 $SNDD Crawfish Bash?

They own majority of company?

So they own 880,130,000 shares out of the 1.4 billion?

Outstanding Shares......1,401,916,607 when they went to expert market

Probably looking at appeal after ruling.

I would imagine same timeline

By design no dog.

"Lots of sketchy characters running these outfits"

True. This management is not one.

Not true

Be safe out there. Enjoy good food and drink and family. Happy Labor Day weekend!

Thats more than half the Outstanding Shares

1,401,916,607

04/14/2022


Wow!

Dream Team!

Oh wow!

I remember buying the day this news came out. This board was very excited. https://www.nasdaq.com/press-release/redhawk-holdings-selects-pcg-advisory-for-investor-relations-and-strategic

https://pcgadvisory.com/

How does this firm treat their other clients?

So cant they get current or go to another exchange or get a PE buyout while also getting legal stuff solved?

OTC looks done. That is all we have heard

Section 4 - Matters Related to Accountants and Financial Statements

 

Item 4.01. Changes in Registrant’s Certifying Accountant.  

 

RedHawk Holdings Corp., a Nevada corporation (the “Company”) and the Audit Committee of the Company’s board of directors, continuously evaluate the ever-increasing cost and benefit of maintaining the Company’s listing as an OTC-Pink public company.

 

The Company is currently delinquent in filing its annual report for the twelve month period ended June 30, 2021 and the quarterly reports for the three month period ended September 30, 2021, the three and six month periods ended December 31, 2021, and the three and nine month periods ended March 31, 2022.

 

At this time, the Company has not announced a specific timetable to cure the Company’s financial statement filing delinquencies and has communicated such with MaloneBailey, LLP (“MaloneBailey”), the Company's independent registered public accounting firm.

 

MaloneBailey has served as the Company's independent registered public accounting firm since January 4, 2021 and reviewed the Company’s quarterly financial statements for the three and six month periods ended December 31, 2020 and the three and nine month periods ended March 31, 2021.

 

On July 28, 2022, the Company received written notification from MaloneBailey that they have resigned as the Company’s auditors at this time. The Company said it would strongly consider re-engaging MaloneBailey when it decides on and announces a specific timetable to cure the Company’s financial statement filing delinquencies.

 

In connection with the interim quarterly periods for the three and six month periods ended December 31, 2020 and the three and nine month periods ended March 31, 2021, there were no disagreements, as contemplated by Item 304(a)(1)(iv) of Regulation S-K (“Regulation S-K”) under the Securities Act of 1933, as amended, between MaloneBailey and the Company on any matter of accounting principles or practices, financial statement disclosure, or scope or procedure, which disagreements, if not resolved to MaloneBailey’s satisfaction, would have caused MaloneBailey to make reference to the subject matter thereof in connection with the review for such interim quarterly periods.

 

The Company has provided MaloneBailey with a copy of the disclosures it is making in this Current Report on Form 8-K and requested from MaloneBailey a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with such disclosures. A copy of MaloneBailey’s letter dated August 3, 2022 is attached as Exhibit 16.1 hereto. 

 

 

It aint gonna be this year

Your positive posts and DD have been good since we have been on expert. Appreciate your posts here

All those 8ks have been filled since we have been on expert market. Things are definitely happening. People here say to be patient and let Mr. Klug go to work for him and us.

Item 1.01Entry into Material Definitive Agreement.

 

The Registrant announced today that it now offers for sale certain real time SARS-CoV2-RT-PCR clinical tests (“Clinical Test Kits”) and SARS-CoV-2 Antigen Rapid Self Tests (“Home Test Kits”). The Clinical Test Kits and Home Test Kits offered for sale have received Emergency Use Authorization from the United States Food and Drug Administration (“FDA EUA”).

 

COVID-19 is a respiratory disease caused by infection with SARS-CoV-2 virus. Common signs of infection include respiratory symptoms, fever, cough, breathing difficulties. In severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and death.

The Clinical Test Kits, manufactured in the United States, are intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal swabs and sputum from patients suspected of COVID-19 by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

The Clinical Test Kits are a real-time reverse transcription polymerase chain reaction test that includes the assays and controls for a real time RT-PCR test for the qualitative detection of RNA from SARS-CoV-2 in nasopharyngeal swab, oropharyngeal swab and sputum specimens from patients who are suspected of COVID-19.

 

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in sputum and upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infective status.

 

The Clinical Test Kits are intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.

 

The Home Test Kits are one-step lateral flow chromatographic immunoassay. The test strip in the device includes: (i) a conjugate pad containing anti-SARS-CoV-2’s Nucleocapsid protein antibody, Mouse IgG antibody, all of which are conjugated to colloidal gold, and (ii) nitrocellulose membrane containing a test line (“T-line”) and a control line (“C-line”).

 

The T-line is coated with anti-SARS-CoV-2’s Nucleocapsid protein antibody, when the specimen is added, it migrates by capillary diffusion rehydrating the gold conjugate, if present in the specimen, SARS-CoV-2’s Nucleocapsid protein and its antibody labeled with colloidal gold formed antigen-antibody complexes. These complexes will continue to migrate along the strip until the T-line, where they are captured by the SARS-CoV-2’s Nucleocapsid protein antibody generating a red violet line in T-line. If the specimen does not contain SARS-CoV-2 or the SARS-CoV-2 is below the lower level, the T-line will not appear.

 

The C-line is coated with Goat anti-Mouse IgG which should bind to the gold-Mouse IgG antibodies conjugate and form a red violet line regardless of the presence of SARS-CoV-2’s Nucleocapsid protein.

 

The purchase of the Clinical Test Kits and the Home Test Kits is subject to certain terms and conditions including, but not limited to, product inspection, product testing, and acceptance. The agreement to purchase the Clinical Test Kits and the Home Test Kits is cancelable, among other things, upon the occurrence of material adverse changes in market conditions or the manufacturer’s loss of its FDA EUA. 

 

Item 1.01Entry into Material Definitive Agreement.

 

The Registrant announced today that it agreed to now offer for sale vacuum blood collection tubes (“VBCT”).

 

A VBCT is a glass or plastic test tube with a colored rubber stopper that creates a vacuum seal inside of the tube, facilitating the drawing of a predetermined volume of liquid. VBCT may contain additives designed to stabilize and preserve the specimen prior to analytical testing. VBCT are available with a safety-engineered stopper, with a variety of labeling options and draw volumes.

 

When a VBCT is inserted into the clear plastic sheath attached to the blood collection tube, its rubber cap is punctured by an inner needle and the vacuum in the tube pulls blood through the needle and into the VBCT. The filled VBCT is then removed, and another can be inserted and filled the same way. The amount of air evacuated from the VBCT predetermines how much blood will fill the VBCT before blood stops flowing.

 

VBCT often include additives that mix with the blood when collected. Each VBCT is topped with a color-coded plastic or rubber cap, and the color of each tube's plastic cap indicates which additives it contains. The meanings of the various VBCT colors are standardized across manufacturers.

 

The additives in the VBCT may include anticoagulants (EDTA, sodium citrate, heparin) or a gel with density between those of blood cells and blood plasma. Additionally, some VBCT contain additives that preserve certain components of or substances within the blood, such as glucose. When a VBCT is centrifuged, the materials within are separated by density, with the blood cells sinking to the bottom and the plasma or serum accumulating at the top. Tubes containing gel can be easily handled and transported after centrifugation without the blood cells and serum mixing.

 

VBCT may contain additional substances that preserve blood for processing in a medical laboratory. Using the wrong VBCT may make the blood sample unusable for the intended purpose. These additives are typically thin film coatings applied by the factory using an ultrasonic nozzle.

 

The shelf life of the VBCT expire over time because the vacuum is lost, and blood will not be drawn into the tube when the needle punctures the cap.

 

VBCT are also used as a medium to transport COVID-19 test specimens to PCR testing laboratories and are among the basic medical supplies taken by disaster relief programs to affected area.

 

Recent developments.

Item 8.01Other Events

 

The Registrant confirmed today that it is in discussions with a leading healthcare provider (“Provider”) of pharmaceutical care and clinical services in the United States with the mutual objective (i) to reach an agreement to install the Registrant’s SANDD Pro™ needle incineration devices in each of the Provider’s pharmacies and clinics in order to reduce the Provider’s needle disposal costs and eliminate incidents of workplace needle stick injuries; and (ii) to reach an agreement for the Provider to offer to the public in each of its pharmacies the over-the-counter “white label” sale of the Registrant’s SANDD mini™.

Most here think we are not going back to OTC. Maybe Private Equity buyout or listed on another exchange is our hope.

Section 4 - Matters Related to Accountants and Financial Statements

 

Item 4.01. Changes in Registrant’s Certifying Accountant.  

 

RedHawk Holdings Corp., a Nevada corporation (the “Company”) and the Audit Committee of the Company’s board of directors, continuously evaluate the ever-increasing cost and benefit of maintaining the Company’s listing as an OTC-Pink public company.

 

The Company is currently delinquent in filing its annual report for the twelve month period ended June 30, 2021 and the quarterly reports for the three month period ended September 30, 2021, the three and six month periods ended December 31, 2021, and the three and nine month periods ended March 31, 2022.

 

At this time, the Company has not announced a specific timetable to cure the Company’s financial statement filing delinquencies and has communicated such with MaloneBailey, LLP (“MaloneBailey”), the Company's independent registered public accounting firm.

 

MaloneBailey has served as the Company's independent registered public accounting firm since January 4, 2021 and reviewed the Company’s quarterly financial statements for the three and six month periods ended December 31, 2020 and the three and nine month periods ended March 31, 2021.

 

On July 28, 2022, the Company received written notification from MaloneBailey that they have resigned as the Company’s auditors at this time. The Company said it would strongly consider re-engaging MaloneBailey when it decides on and announces a specific timetable to cure the Company’s financial statement filing delinquencies.

 

In connection with the interim quarterly periods for the three and six month periods ended December 31, 2020 and the three and nine month periods ended March 31, 2021, there were no disagreements, as contemplated by Item 304(a)(1)(iv) of Regulation S-K (“Regulation S-K”) under the Securities Act of 1933, as amended, between MaloneBailey and the Company on any matter of accounting principles or practices, financial statement disclosure, or scope or procedure, which disagreements, if not resolved to MaloneBailey’s satisfaction, would have caused MaloneBailey to make reference to the subject matter thereof in connection with the review for such interim quarterly periods.

 

The Company has provided MaloneBailey with a copy of the disclosures it is making in this Current Report on Form 8-K and requested from MaloneBailey a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with such disclosures. A copy of MaloneBailey’s letter dated August 3, 2022 is attached as Exhibit 16.1 hereto. 

 

 

On expert market due to several reports not filed. Most here say that was done by design.

Share Structure

Market Cap 

280,383

08/26/2022

Authorized Shares

2,000,000,000

04/14/2022

Outstanding Shares

1,401,916,607

04/14/2022

Ok. Thanks. Hope you two are right

Hope ao!

.10?

So we just wait fo 8k's?

So what are the best outcomes for are $SNDD shares then?

Is Private Equity really an option?

Heard anything?

Any communication for us?

Buy early and often when we trade again! Go Hawk Go!